ORLANCE, INC.
Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens
Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens is a funding opportunity from ORLANCE, INC., up to 300000, closing July 31, 2026.
Jul 31, 2026
(0d left)Overview
PROJECT SUMMARY The currently marketed seasonal influenza vaccines have considerable impact on disease, but their efficacy relies on successfully matching the vaccine strains to future circulating virus strains. These vaccines induce neutralizing antibodies primarily against the head region of hemagglutinin and to a…